Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy [Corrigendum]


On page 50, Table 1, Note section, “MTD 2 mg/m² but 1.4 mg/m² recommended for subsequent studies”. Should have been included.

On page 50, Table 2, the 4th column heading should have been “Patients”, and the 5th column heading should have been “Median Prior Chemotherapy Regimens”.

On page 51, paragraph 4, the sentence “Overall, peripheral neuropathy was observed in 31 (59.6%) patients at any grade” should have been “Overall, peripheral neuropathy was observed in 36 (59.6%) patients at any grade”.

On page 54, Future directions heading, 1st paragraph, “A Phase III study comparing eribulin with paclitaxel in the first-line and second-line treatment of HER2-negative MBC is currently recruiting patients in centers in the USA.” Should have cited reference 58.

On page 54, Future directions heading, 1st paragraph, “For HER2-positive MBC, taxanes combined with trastuzumab have yielded ORRs of 69%–76% and median PFS rates of 9–12 months.” Should have been “For HER2-positive MBC, taxanes combined with trastuzumab have yielded ORRs of 69%–76% and median TTP rates of 9–12 months.”

On page 54, Future directions heading, 1st paragraph, “A Phase III study comparing eribulin with paclitaxel in the first-line and second-line treatment of HER2-negative MBC is currently recruiting patients in centers in the USA.” Should have cited reference 58.

On page 54, Future directions heading, 1st paragraph, “For HER2-positive MBC, taxanes combined with trastuzumab have yielded ORRs of 69%–76% and median PFS rates of 9–12 months.” Should have been “For HER2-positive MBC, taxanes combined with trastuzumab have yielded ORRs of 69%–76% and median TTP rates of 9–12 months.”